Total Funding
42
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
PAION is a biopharmaceutical company developing and commercializing drug candidates for diseases with substantial unmet medical needs.
- James Phillips: Chief Executive Officer
- Abdelghani Omari: Chief Financial Officer
About the Company
PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that engages in developing and commercializing drug candidates for diseases or interventions with a substantial unmet medical need.
The company’s lead compound is remimazolam, an intravenous, ultra-short-acting, and controllable benzodiazepine
sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside. The product can be used for general anesthesia in Europe and procedural sedation in the United States.
It was founded in 2000 and is based in Aachen, Nordrhein-Westfalen, Germany.
